Wealth Enhancement Advisory Services LLC Buys New Position in Amneal Pharmaceuticals, Inc. $AMRX

Wealth Enhancement Advisory Services LLC bought a new stake in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) in the 2nd quarter, Holdings Channel.com reports. The firm bought 13,370 shares of the company’s stock, valued at approximately $113,000.

Other large investors have also added to or reduced their stakes in the company. Janney Montgomery Scott LLC lifted its holdings in Amneal Pharmaceuticals by 26.9% during the first quarter. Janney Montgomery Scott LLC now owns 19,350 shares of the company’s stock valued at $162,000 after purchasing an additional 4,100 shares in the last quarter. Allspring Global Investments Holdings LLC lifted its holdings in Amneal Pharmaceuticals by 53.4% during the first quarter. Allspring Global Investments Holdings LLC now owns 60,567 shares of the company’s stock valued at $508,000 after purchasing an additional 21,079 shares in the last quarter. Amalgamated Bank lifted its holdings in Amneal Pharmaceuticals by 33.0% during the first quarter. Amalgamated Bank now owns 5,511 shares of the company’s stock valued at $46,000 after purchasing an additional 1,367 shares in the last quarter. Acadian Asset Management LLC lifted its holdings in Amneal Pharmaceuticals by 51.3% during the first quarter. Acadian Asset Management LLC now owns 2,598,294 shares of the company’s stock valued at $21,759,000 after purchasing an additional 880,471 shares in the last quarter. Finally, SG Americas Securities LLC lifted its holdings in Amneal Pharmaceuticals by 28.5% during the first quarter. SG Americas Securities LLC now owns 95,761 shares of the company’s stock valued at $802,000 after purchasing an additional 21,243 shares in the last quarter. Hedge funds and other institutional investors own 31.82% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have weighed in on the stock. JPMorgan Chase & Co. lifted their price target on shares of Amneal Pharmaceuticals from $12.00 to $14.00 and gave the company an “overweight” rating in a report on Tuesday, September 16th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Amneal Pharmaceuticals in a report on Wednesday, October 8th. Four research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $12.00.

Amneal Pharmaceuticals Stock Performance

AMRX stock opened at $9.97 on Monday. Amneal Pharmaceuticals, Inc. has a one year low of $6.68 and a one year high of $10.68. The company’s fifty day moving average price is $9.58 and its 200-day moving average price is $8.37. The company has a market capitalization of $3.13 billion, a PE ratio of 998.00 and a beta of 1.18.

Amneal Pharmaceuticals (NASDAQ:AMRX) last released its earnings results on Monday, July 21st. The company reported $0.21 EPS for the quarter. Amneal Pharmaceuticals had a net margin of 0.12% and a negative return on equity of 189.49%. The firm had revenue of $695.42 million for the quarter. Amneal Pharmaceuticals has set its Q2 2025 guidance at EPS. On average, research analysts predict that Amneal Pharmaceuticals, Inc. will post 0.53 EPS for the current fiscal year.

Insider Buying and Selling at Amneal Pharmaceuticals

In related news, EVP Nikita Shah sold 6,340 shares of the company’s stock in a transaction on Monday, August 25th. The shares were sold at an average price of $9.50, for a total transaction of $60,230.00. Following the sale, the executive vice president owned 146,403 shares of the company’s stock, valued at $1,390,828.50. This represents a 4.15% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Andrew S. Boyer sold 279,244 shares of the company’s stock in a transaction on Wednesday, August 20th. The shares were sold at an average price of $9.38, for a total transaction of $2,619,308.72. Following the sale, the executive vice president directly owned 152,426 shares in the company, valued at approximately $1,429,755.88. The trade was a 64.69% decrease in their position. The disclosure for this sale can be found here. Insiders sold 609,206 shares of company stock worth $5,700,625 in the last ninety days. Company insiders own 26.56% of the company’s stock.

Amneal Pharmaceuticals Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.